197 related articles for article (PubMed ID: 38276003)
1. Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis.
Krzysztofik M; Brzewski P; Cuber P; Kacprzyk A; Kulbat A; Richter K; Wojewoda T; Wysocki WM
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38276003
[TBL] [Abstract][Full Text] [Related]
2. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Wu S; Xu Y; Yang L; Guo L; Jiang X
Front Immunol; 2023; 14():1294416. PubMed ID: 38106423
[TBL] [Abstract][Full Text] [Related]
3. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis.
Liu R; Wan Q; Zhao R; Xiao H; Cen Y; Xu X
Cancer Cell Int; 2021 Nov; 21(1):614. PubMed ID: 34809619
[TBL] [Abstract][Full Text] [Related]
4. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
[TBL] [Abstract][Full Text] [Related]
5. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
6. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.
Eder L; Mylvaganam S; Pardo Pardo J; Petkovic J; Strand V; Mease P; Colaco K
Lancet Rheumatol; 2023 Dec; 5(12):e716-e727. PubMed ID: 38251562
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Yang F; Lu C; Wang Y; Liu H; Leng X; Zeng X
Clin Rheumatol; 2023 Jun; 42(6):1593-1605. PubMed ID: 36763226
[TBL] [Abstract][Full Text] [Related]
8. Skin cancer in patients with psoriasis.
Egeberg A; Thyssen JP; Gislason GH; Skov L
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1349-53. PubMed ID: 26932589
[TBL] [Abstract][Full Text] [Related]
9. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
11. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
12. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.
Archier E; Devaux S; Castela E; Gallini A; Aubin F; Le Maître M; Aractingi S; Bachelez H; Cribier B; Joly P; Jullien D; Misery L; Paul C; Ortonne JP; Richard MA
J Eur Acad Dermatol Venereol; 2012 May; 26 Suppl 3():22-31. PubMed ID: 22512677
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
14. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.
Hwang JK; Ricardo JW; Lipner SR
Am J Clin Dermatol; 2023 Sep; 24(5):695-720. PubMed ID: 37209391
[TBL] [Abstract][Full Text] [Related]
16. Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.
Smith SD; Stratigos A; Augustin M; Carrascosa JM; Grond S; Riedl E; Xu W; Patel H; Lebwohl M
Dermatol Ther (Heidelb); 2023 Aug; 13(8):1773-1787. PubMed ID: 37351831
[TBL] [Abstract][Full Text] [Related]
17. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.
Loft ND; Vaengebjerg S; Halling AS; Skov L; Egeberg A
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1151-1160. PubMed ID: 31721310
[TBL] [Abstract][Full Text] [Related]
18. Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis.
Wang X; Liu Q; Wu L; Nie Z; Mei Z
J Cancer; 2020; 11(5):1047-1055. PubMed ID: 31956351
[No Abstract] [Full Text] [Related]
19. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
D'Urso DF; Chiricozzi A; Pirro F; Calabrese L; Caldarola G; Fossati B; De Simone C; Peris K
G Ital Dermatol Venereol; 2020 Aug; 155(4):411-420. PubMed ID: 32545945
[TBL] [Abstract][Full Text] [Related]
20. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review.
Wang J; Wang C; Liu L; Hong S; Ru Y; Sun X; Chen J; Zhang M; Lin N; Li B; Li X
Front Immunol; 2023; 14():993057. PubMed ID: 36817423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
